简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:BENGALURU, Aug 18 (Reuters) - Shares of Indias Concord Biotech (CONB.NS) settled 27.2% higher at 942
BENGALURU, Aug 18 (Reuters) - Shares of Indias Concord Biotech (CONB.NS) settled 27.2% higher at 942.8 rupees in their trading debut on Friday, valuing the biopharma company at more than 98.63 billion rupees ($1.19 billion) in a dull market.
The Ahmedabad, Gujarat-based company opened at 900.05 rupees, a 21.5% premium to its initial public offer (IPO) price of 741 rupees.
It rose as much as 33.3% during the day, hitting its highest at 987.7 rupees.
Founded in 2000, Concord Biotech makes active pharmaceutical ingredients - the key biologically active elements in a drug - as well as finished dosages.
\“Even in a subdued equity market, Concord has managed to list above the streets expectations of a 15% gain,\” said Prashant Tapse, senior vice president of research at Mehta Equities.
\“We are optimistic (about) the companys fermentation and API businesses as well as the global biopharma sector in the long term.\”
The surge in trading debut comes when Indian benchmarks have retreated from record highs due to moderating foreign investor inflows, worries over U.S. Federal Reserves interest rate hikes and growth concerns in China.
Indias benchmark Nifty 50 (.NSEI) and S&P BSE Sensex (.BSESN) closed 0.28% and 0.31% lower, respectively.
Concords IPO comprised 20.9 million shares on offer from existing stakeholders, according to its prospectus, implying the proceeds would go to the selling shareholders alone and not the company.
The 15.51 billion-rupees offering was subscribed 24.87 times, according to NSE data.
\“The companys strong fundamentals and good subscription levels were positive factors. Investors should consider booking profits post-listing,\” said Anubhuti Mishra, equity research analyst at Swastika Investmart.
Earlier this year, a rally in Indias equity market, fuelled by improved domestic sentiment, fired up stock listings, with Mankind Pharma (MNKI.NS), Blackstones Nexus Select Trust (NEXE.NS) and drone maker ideaForge Technology (IDEF.NS) all surging in their trading debuts.
($1 = 83.1180 Indian rupees)
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.